NASDAQ:EOLSEvolus Stock Price, Forecast & News

Evolus' stock was trading at $5.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EOLS shares have decreased by 44.0% and is now trading at $3.31.
View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Evolus.

Evolus is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Evolus.

Evolus will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Evolus Inc (NASDAQ:EOLS) announced its quarterly earnings results on Monday, May, 11th. The company reported ($0.75) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.03. The firm earned $10.50 million during the quarter, compared to analysts' expectations of $16.91 million. Evolus had a negative net margin of 217.51% and a negative return on equity of 197.30%.
View Evolus' earnings history.

8 Wall Street analysts have issued twelve-month target prices for Evolus' stock. Their forecasts range from $3.00 to $30.00. On average, they expect Evolus' stock price to reach $11.88 in the next twelve months. This suggests a possible upside of 258.8% from the stock's current price.
View analysts' price targets for Evolus.

Media headlines about EOLS stock have trended neutral recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evolus earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about Evolus.

Evolus saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 5,000,000 shares, an increase of 14.7% from the June 15th total of 4,360,000 shares. Based on an average daily trading volume, of 871,900 shares, the short-interest ratio is presently 5.7 days. Approximately 22.8% of the company's shares are short sold.
View Evolus' Current Options Chain.

Some companies that are related to Evolus include BioDelivery Sciences International (BDSI), BELLUS Health (BLUSF), Avid Bioservices (CDMO), Puma Biotechnology (PBYI), Catalyst Pharmaceuticals (CPRX), Rigel Pharmaceuticals (RIGL), Zafgen (ZFGN), Liminal BioSciences (LMNL), Spectrum Pharmaceuticals (SPPI), 89bio (ETNB), Xenon Pharmaceuticals (XENE), Avedro (AVDR), Kamada (KMDA), MannKind (MNKD) and Neoleukin Therapeutics (NLTX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), Advanced Micro Devices (AMD), Revance Therapeutics (RVNC), Camtek (CAMT), Plug Power (PLUG), Micron Technology (MU), Canopy Growth (CGC), Tandem Diabetes Care (TNDM), Calithera Biosciences (CALA) and JD.Com (JD).

(EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Evolus' stock is owned by a variety of institutional and retail investors. Top institutional investors include UBS Group AG (0.19%). Company insiders that own Evolus stock include Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Michael M Jafar, Rui Avelar, Simone Blank and Vikram Malik.
View institutional ownership trends for Evolus.

EOLS stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have bought Evolus stock in the last two years include David N Gill, Kristine Romine, Michael M Jafar, Simone Blank, and Vikram Malik.
View insider buying and selling activity for Evolus.

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EOLS stock can currently be purchased for approximately $3.31.

Evolus has a market capitalization of $111.64 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Evolus employs 70 workers across the globe.

The official website for Evolus is www.evolus.com.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]